Full-Time
Posted on 8/8/2025
Genetic testing and health screening platform
$195k - $250k/yr
Burlingame, CA, USA
Hybrid
Hybrid position requiring in-office presence.
Color provides genetic testing and health screening services for individuals, healthcare providers, and employers. Its products include genetic tests and health screenings (including COVID-19 testing) that customers can buy directly or through providers, with options for employer health programs. The tests work by collecting a sample from the user, analyzing genetic data and health markers, and delivering results through Color’s platform, along with access to genetic counseling to help interpret findings. The company differentiates itself through its broad accessibility (direct-to-consumer, provider and employer partnerships), emphasis on privacy and data security, and a combination of preventive health insights with counseling. Color’s goal is to make genetic testing and preventive health screenings affordable and accessible to improve individual and workplace health and productivity.
Company Size
501-1,000
Company Stage
Series E
Total Funding
$482M
Headquarters
Burlingame, California
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Competitive salary
Comprehensive medical, dental, vision, life, and disability benefits. Including employer HSA contributions.
401(k) match
Monthly lunch, phone, and wifi stipend for remote employees
Generous vacation policy, paid holidays and company-wide recharge days
Monthly stipend to spend on your well being
Equal paid parental leave for birthing and non-birthing parents
Four complementary clinical-grade genetic testing kits for you and your family
Dr. Karen knudsen joins Color as Strategic Advisor. Published March 31, 2026 Color is honored to welcome Karen E. Knudsen, MBA, PhD, as a Strategic Advisor to Color Health. Dr. Karen knudsen joins Color Health as strategic advisor. Dr. Knudsen is the Chief Executive Officer of the Parker Institute for Cancer Immunotherapy (PICI) and a globally recognized cancer scientist and healthcare leader. Throughout her career, she has helped shape the future of cancer research, care delivery, and collaboration across the oncology ecosystem. In her prior role as the CEO of the American Cancer Society, Dr. Knudsen helped shape Color's Virtual Cancer Clinic (VCC). Today, the Color VCC is the only nationwide, oncologist-led cancer care platform, bringing high-quality, comprehensive cancer care to patients regardless of where they live. At PICI, Dr. Knudsen is leading efforts to advance bold science and accelerate breakthrough immunotherapies through cross-institutional collaboration. With more than 100 active studies spanning clinical trials, preclinical discoveries, and emerging technologies, the institute is helping bring innovative immune-based treatments to patients faster. At Color, Dr. Knudsen will help guide the continued evolution and expansion of the VCC and support its mission to deliver accessible, high-impact cancer care at scale for employer, union, health plan and public sector populations. As Dr. Knudsen shares: "Transforming cancer outcomes requires both scientific innovation and new models for delivering care. Color's innovation on the care delivery front has been truly game changing since the launch of its Virtual Cancer Clinic, with plenty of room to grow. The Color VCC detects cancer earlier through guidelines-based screening, while improving outcomes and costs at every stage. Utilizing risk-based assessments, at-home screening and in-networking imaging through its integrated clinical platform, Color's model has already produced impressive results. The VCC has been shown to increase screening adherence by 77%, and cut time to diagnosis by 66%, getting patients into the right treatment in days, not months. I'm excited to once again work with Color to continue innovating on best-in-class cancer care delivery to those in need, at every stage." Color is incredibly fortunate to partner with Dr. Knudsen as Color continue building the future of cancer care. Welcome to Color, Karen!
Lotus Health AI has raised $35 million in a Series A round co-led by Kleiner Perkins and CRV, bringing total funding to $41 million. CRV general partner Saar Gur, who led early investments in DoorDash and Ring, will join the board. The San Francisco-based startup combines medical AI, unified patient data and board-certified physicians to deliver primary care at scale. The platform syncs medical records, labs and wearable data, supporting over 50 languages with 24/7 availability. Physicians review AI-generated guidance and prescribe medications when needed. Lotus generates revenue through premium sponsorships rather than patient billing, aiming to make care accessible without insurance. Investors include Joe Montana's Liquid 2, healthcare founders from Clover Health and Color Genomics, and physicians from Harvard and Stanford.
Maven Clinic and Color Health have partnered to integrate fertility preservation into cancer care, creating an oncofertility programme initially available through employers and health plans. The collaboration combines Color's oncologist-led cancer care with Maven's women's health platform to help cancer patients understand and preserve fertility options. Cancer rates among young adults are rising, with roughly 70,000 diagnosed annually, yet only 50% of patients discuss fertility preservation with their oncologist. Cancer treatments can permanently impact fertility, making early intervention critical. Through the partnership, Color patients of childbearing age will access Maven's oncofertility care pathway, including virtual teams of oncologists, fertility specialists and mental health providers. Services cover egg, sperm and embryo freezing, plus expedited access to Maven's network of fertility clinics. The programme aims to make fertility preservation a standard part of cancer care rather than an afterthought.
New uses for Google health AI aim to democratize patient care. Hackensack Meridian and Color are using Google's AI tools to speed up patient access and improve care. Also, Catalyst is using the cloud service to automate patient consent for clinical trials through EHRs via the HL7 FHIR data exchange standard. Google Cloud showcased new artificial intelligence tools and AI agents this week. The company says they could help healthcare and other organizations unlock new returns on investment and reshape how healthcare is delivered, accessed and improved. "In healthcare, the top use cases are in tech support (53%), security operations and cybersecurity (49%), productivity and research (46%) and patient experience (44%)," said Aashima Gupta, Google Cloud's global director of healthcare strategy and solutions, and Shweta Maniar, its global director of life science strategy and solutions. Several healthcare organizations are showcasing how they're putting the tools to work. New Jersey-based Hackensack Meridian Health announced that it is using Google AI through integrations with its electronic health records, while California-based Color has launched an AI assistant to automate breast cancer screening eligibility and scheduling. New York-based Castor also introduced the Catalyst AI platform to automate patient enrollment and consent processes in clinical trials. Improving flows to benefit patients. Patient experiences are inextricably linked to both the speed and quality of care, and healthcare consumers want to see healthcare rapidly adopt digital patient engagement and data-driven decision-making. "The ongoing transition to value-based care models emphasizes patient outcomes and cost-efficiency, making digital tools that empower patients to actively participate in their own care even more essential," David Nickelson, senior partner and consulting lead, health and life science, Randstad Digital, told Healthcare IT News in January. Hackensack Meridien, like many health systems, is using AI to deploy clinical note summarization. Relying on Google Gemini, 12 specialties now have access to genAI capabilities in their Epic Systems EHR, according to Sameer Sethi, the health system's senior vice president and chief AI officer. "With the help of Google, we try to build these capabilities and then integrate into clinical workflow," he said during a media roundtable hosted by Google on Tuesday. "It's as simple as framing that right within Epic," he explained, noting that the health system is also building prediction models through an integration into its EHR. The health system said it is not only reducing the time specialty staff spend in EHR workflows by between 5% and 20%, but it has also built an AI-powered lab summarization agent that enables patients to get their test results faster and understand them better. The AI agent summarizes lab panel results, highlights significant trends and key findings, and generates preventive care recommendations for primary care physicians to use when drafting messages to patients about their lab results. The tool speeds up communications to patients and leads to faster follow-up and timelier preventive actions, the health system said in a statement on Thursday. The third way Hackensack Meridian said it is using AI is by immediately equipping its Neonatal Intensive Care Unit nurses with knowledge, regardless of their current workload or experience level. With rapid access to the most current NICU best practices and policies through the NICU Nurse Agent, the health system said it aims to ensure that the highest standards of care are met in the unit. While it is looking to AI to stop the erosion of clinician well-being and the pervasive discontinuity of patient journeys, Hackensack Meridian said its overall AI strategy is creating a scalable, replicable model for value-based care. The approach moves beyond "incremental optimizations," and the strategic AI deployments address healthcare's "most entrenched systemic crises," Gupta said in the statement. "They are establishing the blueprint for the next generation of [VBC]." Democratizing patient access. California-based Color developed a new AI platform on Google Cloud Vertex AI to democratize patient care through its Virtual Cancer Clinic. With the launch of Color Assistant on Thursday, the company said it is targeting the 20 - 30% of eligible women in the United States who are not up to date on their mammograms in order to tackle the concerning breast cancer metrics for women under the age of 50. Diagnosis rates have increased by nearly 20% since the early 2000s among that population. "We know how to stop late-stage breast cancer diagnoses through screening, but we need to make getting that screening much easier," said Color CEO and cofounder Othman Laraki in the announcement. The assistant determines eligibility for mammograms, schedules breast cancer screenings and coordinates follow-up, making them more widely and easily accessible to all patients through an initiative that runs through Dec. 31. An automated bot answers questions and sets up mammograms through integrations with EHR systems, Laraki explained on Tuesday at the media briefing. The virtual assistant, powered by the Gemini 2.5 family of models, also maintains clinical oversight, making it possible to serve a general population, he said. The agentic framework relies on the American Cancer Society and other evidence-based guidelines. But the assistant requests clinical reviews by clinicians within Color's 50-state medical group, and its care teams connect with those eligible for a mammogram for any necessary clarifications and to coordinate appointments. They can also order other types of imaging in accordance with clinical guidelines, the company said. To close the loop and improve patient access, Color's clinicians receive and deliver screening results directly to patients and then coordinate next steps for abnormal findings with the patients' existing care providers. The new agent also checks transcripts to ensure quality results, Laraki noted. "There are some parts of healthcare where AI can truly make abundance," he said. Patient enrollment in clinical trials. Castor, a clinical trial technology company, released its Catalyst AI-powered platform developed on Google Cloud to automate tasks in clinical studies on Thursday. The "self-driving" platform automates processes and compresses overall timeframes for administrative tasks, with its data-entry and verification skills launched through patient-mediated retrieval pathways. That includes speeding up the rates of patient enrollment and consent through digital integrations with EHRs. The agent requests and retrieves patient consent using the HL7 FHIR standard, the company said in its announcement. The AI platform and its event-driven data infrastructure, which the company said took 18 months to build, are designed to provide full observability, auditability and regulatory readiness for clinical studies. "Without a detailed understanding of what's actually happening in a study, you simply can't apply AI effectively," Derk Arts, Castor's CEO, said in a statement. Andrea Fox is senior editor of Healthcare IT News. Email: [email protected] Healthcare IT News is a HIMSS Media publication.
Google Cloud unveils health AI agent partnerships. The technology giant is working with Hackensack Meridian Health on multiple agents, including a tool that can summarize patients' medical records for providers. Google Cloud revealed several artificial intelligence partnerships with healthcare organizations on Thursday, including for projects that summarize clinical notes and automate prior authorizations. The partnerships come as more healthcare and life science firms are deploying AI agents, or advanced tools that can more autonomously plan and perform tasks, according to a Google Cloud survey of 605 leaders released Thursday. Forty-four percent of executives said their organizations were actively using agents, with 34% reporting they use 10 or more agents. For example, Hackensack Meridian Health built multiple AI agents using Google's generative AI technology, including a tool that can recap patients' medical records for doctors. The health system's note summarization agent has helped more than 1,200 clinicians generate more than 17,000 summaries since it went live in June, according to a press release. The provider began offering a general summary of patient records, but has since been able to customize results by specialty - so an oncologist may see different, more relevant information compared with a urologist, said Sameer Sethi, SVP, chief AI officer, Hackensack Meridian Health. "We all have been in situations where we go to our physician offices, and the physician is reading the screen while trying to understand and talk to you, right?" he said during the press call. "We're trying to reduce that time that the physician spends on screen looking at the patient chart." The health system is also rolling out two other agents, including an assistant for nurses in Neonatal Intensive Care Units that provides information on best practices and policies, and a tool that summarizes lab results so primary care providers can more quickly draft notes to patients. The technology giant has also partnered with IKS Health, a company that provides revenue cycle, clinical and other operational products, on an AI platform that detects when prior authorization could be required and helps manage the process. Its multi-agent system includes a documentation assistant that creates clinical notes on patient visits, a coding agent that aligns billing codes with documentation and a tool that aims to detect when prior authorization is necessary. That agent works with payer systems to collect administrative and clinical data to support the prior authorization request, executives said. The process also loops in a human worker to ensure the AI is accurate when medically necessary, IKS said. Additionally on Thursday, Google announced a partnership with virtual cancer care company Color Health to launch an AI assistant that helps women determine their eligibility for breast cancer screenings and schedule care.